<code id='05335BEC35'></code><style id='05335BEC35'></style>
    • <acronym id='05335BEC35'></acronym>
      <center id='05335BEC35'><center id='05335BEC35'><tfoot id='05335BEC35'></tfoot></center><abbr id='05335BEC35'><dir id='05335BEC35'><tfoot id='05335BEC35'></tfoot><noframes id='05335BEC35'>

    • <optgroup id='05335BEC35'><strike id='05335BEC35'><sup id='05335BEC35'></sup></strike><code id='05335BEC35'></code></optgroup>
        1. <b id='05335BEC35'><label id='05335BEC35'><select id='05335BEC35'><dt id='05335BEC35'><span id='05335BEC35'></span></dt></select></label></b><u id='05335BEC35'></u>
          <i id='05335BEC35'><strike id='05335BEC35'><tt id='05335BEC35'><pre id='05335BEC35'></pre></tt></strike></i>

          Home / explore / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:9
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In